Birth Control Pills Market

USD 16.0 billion in 2026 to USD 27.0 billion by 2036, recording a 5.4% CAGR.

• As per Fact.MR analysis, the birth control pills market was valued at USD 15.2 billion in 2025.
• Demand will grow from USD 16.0 billion in 2026 to USD 27.0 billion by 2036.
• The market is projected to record a 5.4% CAGR from 2026 to 2036 as contraceptive access, product choice, and reproductive health services shape demand.

Source: Fact.MR analysis. Updated Oct 29, 2026

What are the defining numbers behind Birth Control Pills Market growth?

USD 11.0 billion absolute opportunity between 2026 and 2036.

• Demand Drivers in the Market
  • Demand for birth control pills is supported by the need for reliable contraception and greater access to family planning services. The World Health Organization reported in July 2025 that 1.1 billion women of reproductive age had a need for family planning, including 164 million with an unmet need for contraception, based on 2021 estimates [1].
  • Availability of different oral contraceptive formulations gives individuals greater choice based on their health needs and preferences. The WHO distinguishes combined oral contraceptives from progestin-only pills, which differ in hormonal composition and suitability. [2].
  • Women’s healthcare research and commercial partnerships may support product development and regional availability. In February 2026, Gedeon Richter Plc. and Fuji Pharma announced an expanded strategic collaboration in women’s healthcare, referencing the commercialization of the oral contraceptive Nextstellis in Thailand [3].
• Key Segments Analyzed
  • By Product Type: Combination Pills are projected to account for 54.3% of the market in 2026.
  • By Age Group: Adults will account for 81.6% of the market in 2026.
  • By Distribution Channel: Retail Pharmacies are forecast to hold 51.2% of the market in 2026, supported by their role in dispensing and supplying contraceptive medicines.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “The birth control pills market will depend on access, product choice, and confidence in contraceptive care. Manufacturers and distributors need to support consistent product availability and clear information, while healthcare professionals remain important in helping users choose formulations suited to their individual needs.”
• Strategic Implications
  • Manufacturers should maintain reliable supplies of combination and progestin-only formulations while communicating product-specific instructions and precautions.
  • Retail pharmacies need to support appropriate dispensing practices and provide clear guidance on prescription requirements in each market.
  • Online pharmacies must prioritize regulatory compliance, product authenticity, privacy, and access to qualified healthcare advice where needed.
  • Healthcare providers consider medical history, potential contraindications, side effects, and patient preferences when discussing oral contraception.
  • Pharmaceutical companies evaluate regional partnerships and distribution arrangements to expand access while meeting local regulatory requirements.

Germany is projected to record a 4.2% CAGR through 2036. Brazil is set to post 6.8%, followed by the USA at 4.8%. The UK is forecast to advance at 5.5%, while Japan is projected to record a 6.4% CAGR.

Fact.MR finds that Combination Pills leads Product Type at 54.3%; Adults leads Age Group at 81.6%; and Retail Pharmacies leads Distribution Channel at 51.2% in 2026.

Which Product Type dominates?

Combination Pills hold a 54.3% share in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Combination pills contain estrogen and progestin and represent the largest product category in the market estimates. Progestin-only pills serve users for whom a formulation without estrogen may be appropriate. Extended-cycle pills and other formulations address different dosing schedules and product preferences. The selection of a contraceptive should be based on individual circumstances and suitable healthcare guidance rather than market share alone.

Which Age Group leads the market?

Adults are expected to represent 81.6% of the market in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Adults account for the largest share of the market, reflecting the segmentation. Teenagers also form part of the market for oral contraceptives, subject to local regulations, access arrangements, and individual clinical suitability. WHO guidance recognizes that adolescents can use oral contraceptives when the method is appropriate and supported by suitable healthcare advice. Age-group shares should be interpreted according to the study's classification and underlying market-sizing methodology.

How does Distribution Channel shape demand?

Retail Pharmacies are forecast to account for 51.2% of the market in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Retail pharmacies remain an important route for dispensing and purchasing oral contraceptives. Online pharmacies can offer convenience, particularly where regulated online supply is permitted. Hospital pharmacies may serve users receiving contraceptive advice through hospital or specialist services, while other channels vary by local healthcare systems. The extent to which each channel contributes to sales depends on prescription rules, reimbursement arrangements, distribution infrastructure, and consumer preferences.

Broader contraceptive access and demand for reversible pregnancy prevention support the market, while adherence requirements, side effects, and competition from other contraceptive methods influence adoption.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Source: Fact.MR analysis. Updated Oct 29, 2026

What supports Germany adoption?

4.2% CAGR, driven by availability of combined and progestin-only oral contraceptives.

Germany’s birth control pills market is supported by awareness of reproductive health, established access to gynecological care, and the availability of combined and progestin-only oral contraceptives. Demand is also influenced by individual contraceptive preferences, physician counseling, and access to generic formulations. Changes in contraceptive costs and reimbursement policies can affect affordability and product choice. Key factors include the role of gynecologists in contraceptive decisions, demand for pregnancy prevention, and established pharmacy distribution.

How is Brazil developing birth control pills adoption?

6.8% CAGR, supported by the potential role of public-sector family planning services and access to reversible contraceptives.

Brazil's Ministry of Health identifies combined oral contraceptives and progestin-only pills among the contraceptive methods available through its healthcare system. Its family planning guidance emphasizes access to reliable information and informed choice [4]. Public provision can help support access, although actual market growth will also depend on procurement, availability, affordability, and private-sector demand.

What supports United States adoption?

4.8% CAGR, shaped by consumer access to formulation choice and established retail distribution.

The U.S. National Center for Health Statistics reported in August 2025 that 11.4% of females aged 15–49 used oral contraceptive pills in 2022–2023 [5]. The FDA's approval of Opill for nonprescription use created an additional retail and online access route for a progestin-only pill. Future demand will depend on access, affordability, consumer preferences, and competition from other contraceptive methods.

How is the United Kingdom building adoption?

5.5% CAGR, led by pharmacy access and established sexual and reproductive healthcare services.

NHS England's October 2026 release reported that oral contraceptives accounted for 27% of uptake of user-dependent contraceptive methods at dedicated sexual and reproductive health services in 2025–26. This measure covers those services rather than all contraceptive use in England [6]. Access through pharmacies, primary care, and dedicated services remains relevant to the market's distribution outlook.

What supports Japan adoption?

6.4% CAGR, backed by the potential contribution of women's healthcare product development and regional pharmaceutical partnerships.

Japan's outlook can be influenced by product availability, contraceptive preferences, healthcare access, and the introduction or commercialization of women's healthcare products. In February 2026, Gedeon Richter Plc. and Fuji Pharma announced the strengthening of their women's healthcare collaboration, including reference to Fuji's commercialization of Nextstellis in Thailand [4].

Fact.MR identifies Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Gedeon Richter Plc. as the companies to profile for the competitive landscape. Their relevance should be assessed at the product and portfolio level, because participation in pharmaceuticals or women's healthcare does not automatically establish direct competition across every oral contraceptive category.

Bayer AG has an established women's healthcare business and a portfolio that includes long-acting reversible contraceptives. In July 2026, Bayer announced an agreement for Apollo-managed funds and affiliates to acquire a minority, non-controlling stake in an entity holding its long-acting reversible contraceptives business, with Bayer retaining majority ownership and operational control [7]. This transaction concerns long-acting contraceptives rather than a new birth control pill launch.

Gedeon Richter Plc. has documented activity in women's healthcare and oral contraceptive commercialization. Its February 2026 announcement with Fuji Pharma described the expansion of their strategic collaboration and referenced Nextstellis commercialization in Thailand. This provides a verifiable example of women's healthcare partnership activity.

For Pfizer, Teva Pharmaceutical Industries, and AbbVie, individual oral contraceptive products and current commercial participation should be verified against their official product portfolios and regulatory records before assigning them a direct leadership position in this specific market. No unverified product launch, acquisition, or partnership is attributed to these companies here.

Competition in the market depends on formulation availability, regulatory approvals, product pricing, distribution agreements, manufacturing reliability, and healthcare-provider awareness. Manufacturers also need to account for the different clinical considerations associated with combined and progestin-only pills.

Key companies covered in the competitive set include Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Gedeon Richter Plc..

• Bayer AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Gedeon Richter Plc.

• [1] World Health Organization. (2025, July 3). Family planning/contraception methods.
• [2] World Health Organization. (2025, December 23). Oral contraceptives
• [3] Gedeon Richter Plc. (2026, February 3). Richter and Fuji strengthen strategic collaboration.
• [4] Ministério da Saúde. (n.d.). Contracepção
• [5] Daniels, K., & Abma, J. C. (2025, August). Current contraceptive status among females ages 15–49: United States, 2022–2023 (NCHS Data Brief No. 539). National Center for Health Statistics.
• [6] NHS England. (2026, October 22). Sexual and reproductive health services, England (Contraception), 2025–26contraception-2025-26
• [7] Bayer AG. (2026, July 10). Bayer secures 3.0 billion euros to improve capital structure.

• The report describes demand for oral hormonal contraceptives across the specified product categories.
• Segment analysis compares combination pills, age groups, and distribution channels using the 2026 shares.
• Country analysis discusses Germany, Brazil, the USA, the UK, and Japan alongside relevant official healthcare information.
• The competitive overview profiles Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Gedeon Richter Plc..
• Distribution analysis distinguishes retail pharmacies from online and hospital pharmacy channels.
• The report examines access, product choice, adherence, regulatory requirements, and competition from alternative contraceptive methods.

The market covers oral hormonal contraceptive products used to prevent pregnancy. It includes combination pills containing estrogen and progestin, progestin-only pills, extended-cycle formulations, and other products within the defined classification. The analysis considers demand across age groups and distribution channels, with attention to healthcare access, product availability, regulatory requirements, and consumer preferences.

What is included in the scope?

Included products are oral contraceptive pills intended for pregnancy prevention. The market analysis considers product-type segmentation, age-group demand, retail and online pharmacy distribution, hospital pharmacy supply, country-level market growth, and the competitive activities of the specified pharmaceutical companies where relevant evidence is available.

What is excluded from the scope?

The market excludes contraceptive implants, intrauterine devices, injectable contraceptives, patches, vaginal rings, condoms, and other non-oral contraceptive methods from the defined birth control pills revenue boundary. Emergency contraceptive pills should be included only if they fall within the underlying market definition. General women's healthcare medicines that are not oral contraceptives are also excluded. Pharmaceutical companies' broader revenues should not be counted as birth control pill market revenue.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.